NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Forecast, Price & News

$9.44

-0.28 (-2.88%)

(As of 09/29/2023 ET)

Compare

Today's Range: $9.42
▼
$9.87
50-Day Range: $9.40
▼
$13.32
52-Week Range: $9.18
▼
$21.05

Volume: 486,572 shs
Average Volume: 702,686 shs
Market Capitalization: $595.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

Avid Bioservices MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 111.9% Upside
$20.00 Price Target
Short Interest: Bearish
8.38% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.96
Upright™ Environmental Score
News Sentiment: 0.89
Based on 6 Articles This Week
Insider Trading: Selling Shares
$394,626 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.14) to $0.13 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

458th out of 972 stocks

Pharmaceutical Preparations Industry

203rd out of 452 stocks

3.3

Analyst's Opinion

Consensus Rating
Avid Bioservices has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, Avid Bioservices has a forecasted upside of 111.9% from its current price of $9.44.
Amount of Analyst Coverage
Avid Bioservices has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.38% of the outstanding shares of Avid Bioservices have been sold short.
Short Interest Ratio / Days to Cover
Avid Bioservices has a short interest ratio ("days to cover") of 9.3.
Change versus previous month
Short interest in Avid Bioservices has recently increased by 1.54%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Avid Bioservices does not currently pay a dividend.
Dividend Growth
Avid Bioservices does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Avid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.
Environmental Sustainability
The Environmental Impact score for Avid Bioservices is -0.96.

3.3

News and Social Media Coverage

News Sentiment
Avid Bioservices has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Avid Bioservices this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
5 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avid Bioservices insiders have sold 107.04% more of their company's stock than they have bought. Specifically, they have bought $190,600.00 in company stock and sold $394,626.00 in company stock.
Percentage Held by Insiders
Only 2.39% of the stock of Avid Bioservices is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avid Bioservices are expected to grow in the coming year, from ($0.14) to $0.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avid Bioservices is -236.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avid Bioservices is -236.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avid Bioservices has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Price History

30 days | 90 days | 365 days | Advanced Chart

CDMO Stock News Headlines

October 1, 2023 | americanbankingnews.com

Avid Bioservices, Inc. (NASDAQ:CDMO) Receives $20.00 Consensus Price Target from Analysts

September 30, 2023 | americanbankingnews.com

Avid Bioservices (NASDAQ:CDMO) Coverage Initiated by Analysts at William Blair

October 1, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

September 29, 2023 | msn.com

William Blair Initiates Coverage of Avid Bioservices (CDMO) with Market Perform Recommendation

September 25, 2023 | americanbankingnews.com

Joseph Carleone Acquires 20,000 Shares of Avid Bioservices, Inc. (NASDAQ:CDMO) Stock

September 23, 2023 | finance.yahoo.com

Insider Buying: Director Joseph Carleone Acquires 20,000 Shares of Avid Bioservices Inc (CDMO)

September 8, 2023 | finance.yahoo.com

Q1 2024 Avid Bioservices Inc Earnings Call

September 7, 2023 | seekingalpha.com

Avid Bioservices GAAP EPS of -$0.03 misses by $0.01, revenue of $37.7M beats by $1.61M

October 1, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

September 7, 2023 | finance.yahoo.com

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023

September 6, 2023 | benzinga.com

Earnings Outlook For Avid Bioservices

August 31, 2023 | finance.yahoo.com

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023

August 4, 2023 | seekingalpha.com

Avid Bioservices Shifts To More Growth Amid Costly Expansion Efforts

July 6, 2023 | msn.com

Avid Bioservices (CDMO) Price Target Decreased by 11.24% to 20.15

June 23, 2023 | finance.yahoo.com

Why Avid Bioservices Stock Was Plummeting This Week

June 22, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Accolade (ACCD), Avid Bioservices (CDMO)

June 21, 2023 | seekingalpha.com

Avid Bioservices GAAP EPS of $0.00 misses by $0.01, revenue of $39.8M beats by $0.9M

June 21, 2023 | finance.yahoo.com

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023

June 20, 2023 | seekingalpha.com

Avid Bioservices FQ4 2023 Earnings Preview

June 14, 2023 | finance.yahoo.com

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023

June 8, 2023 | finance.yahoo.com

Should You Invest in Avid Bioservices (CDMO)?

May 3, 2023 | benzinga.com

Director at Avid Bioservices Exercises Options Worth $88K

April 27, 2023 | msn.com

Iqvia, Icon lag contract research rivals after Q1 earnings

April 24, 2023 | finance.yahoo.com

Avid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90

April 17, 2023 | finance.yahoo.com

Improved Earnings Required Before Avid Bioservices, Inc. (NASDAQ:CDMO) Shares Find Their Feet

April 4, 2023 | finance.yahoo.com

Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers

March 14, 2023 | msn.com

Keybanc Upgrades Avid Bioservices (CDMO)

See More Headlines

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings: 9/07/2023
Today: 9/30/2023
Next Earnings (Estimated): 12/05/2023
Fiscal Year End: 4/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDMO
CUSIP: N/A
CIK: 704562
Web: www.avidbio.com
Phone: (714) 508-6100
Fax: 714-838-5817
Employees: 365
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $20.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +111.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $560,000.00
Net Margins: -2.06%
Pretax Margin: -1.96%
Return on Equity: -1.54%
Return on Assets: -0.64%

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 1.53
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $149.27 million
Price / Sales: 3.99
Cash Flow: $0.15 per share
Price / Cash Flow: 63.02
Book Value: $3.02 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 63,110,000
Free Float: 61,605,000
Market Cap: $595.76 million
Optionable: Optionable
Beta: 1.68

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Nicholas Stewart Green B.Sc. (Age 58)
MBA, Pres, CEO & Director
Comp: $1.35M

Mr. Daniel R. Hart (Age 50)
Chief Financial Officer
Comp: $719.75k

Mr. Richard Richieri (Age 58)
Chief Operations Officer
Comp: $561.68k

Mr. Mark R. Ziebell J.D. (Age 59)
VP, Gen. Counsel & Corp. Sec.
Comp: $647.1k

Mr. Matthew Kwietniak (Age 54)
Chief Commercial Officer
Comp: $553.59k

Ms. Oksana Lukash
VP of People

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares.
View CDMO analyst ratings or view top-rated stocks.
What is Avid Bioservices' stock price forecast for 2023?: 3 brokerages have issued 12-month price objectives for Avid Bioservices' shares. Their CDMO share price forecasts range from $15.00 to $25.00. On average, they anticipate the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts.
How have CDMO shares performed in 2023?: Avid Bioservices' stock was trading at $13.77 at the beginning of 2023. Since then, CDMO stock has decreased by 31.4% and is now trading at $9.44.
View the best growth stocks for 2023 here.
When is Avid Bioservices' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our CDMO earnings forecast.
How were Avid Bioservices' earnings last quarter?: Avid Bioservices, Inc. (NASDAQ:CDMO) announced its quarterly earnings results on Thursday, September, 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $37.73 million during the quarter, compared to the consensus estimate of $34 million. Avid Bioservices had a negative net margin of 2.06% and a negative trailing twelve-month return on equity of 1.54%. During the same period in the prior year, the business earned $0.02 EPS.
What ETFs hold Avid Bioservices' stock?: ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX).Invesco S&P SmallCap Health Care ETF (PSCH).
When did Avid Bioservices' stock split?: Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What guidance has Avid Bioservices issued on next quarter's earnings?: Avid Bioservices updated its FY 2024 earnings guidance on Thursday, September, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $155.71 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?: 5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.
What other stocks do shareholders of Avid Bioservices own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).
What is Avid Bioservices' stock symbol?: Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How do I buy shares of Avid Bioservices?: Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Avid Bioservices' stock price today?: One share of CDMO stock can currently be purchased for approximately $9.44.
How much money does Avid Bioservices make?: Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $595.76 million and generates $149.27 million in revenue each year. The biopharmaceutical company earns $560,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.
How many employees does Avid Bioservices have?: The company employs 365 workers across the globe.
How can I contact Avid Bioservices?: Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial